Glesatinib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Glesatinib
Accession Number
DB06302
Type
Small Molecule
Groups
Investigational
Description
Not Available
Structure
Thumb
Synonyms
Not Available
External IDs
MG-90265 / MG-90265X / MG90265 / MG90265X / MGCD-265 / MGCD265
Categories
UNII
7Q29OXD98N
CAS number
936694-12-1
Weight
Average: 619.71
Monoisotopic: 619.152338423
Chemical Formula
C31H27F2N5O3S2
InChI Key
YRCHYHRCBXNYNU-UHFFFAOYSA-N
InChI
InChI=1S/C31H27F2N5O3S2/c1-40-13-12-34-17-20-4-8-24(36-18-20)28-16-25-30(43-28)27(10-11-35-25)41-26-9-7-22(15-23(26)33)37-31(42)38-29(39)14-19-2-5-21(32)6-3-19/h2-11,15-16,18,34H,12-14,17H2,1H3,(H2,37,38,39,42)
IUPAC Name
3-(3-fluoro-4-{[2-(5-{[(2-methoxyethyl)amino]methyl}pyridin-2-yl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)-1-[2-(4-fluorophenyl)acetyl]thiourea
SMILES
COCCNCC1=CC=C(N=C1)C1=CC2=NC=CC(OC3=CC=C(NC(=S)NC(=O)CC4=CC=C(F)C=C4)C=C3F)=C2S1

Pharmacology

Indication

Investigated for use/treatment in cancer/tumors (unspecified).

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
3,5-diiodothyropropionic acidThe therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Glesatinib.
3,5-DiiodotyrosineThe therapeutic efficacy of 3,5-Diiodotyrosine can be decreased when used in combination with Glesatinib.
AbaloparatideThe therapeutic efficacy of Abaloparatide can be decreased when used in combination with Glesatinib.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Glesatinib.
BenzylthiouracilThe therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Glesatinib.
CarbimazoleThe therapeutic efficacy of Carbimazole can be decreased when used in combination with Glesatinib.
DibromotyrosineThe therapeutic efficacy of Dibromotyrosine can be decreased when used in combination with Glesatinib.
ElcatoninThe therapeutic efficacy of Elcatonin can be decreased when used in combination with Glesatinib.
FollitropinThe therapeutic efficacy of Follitropin can be decreased when used in combination with Glesatinib.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Glesatinib.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
52084900
ChEMBL
CHEMBL3989914
Wikipedia
Glesatinib

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentCancer, Advanced1
1CompletedTreatmentAdvanced Malignancies2
1TerminatedTreatmentAdvanced Malignancies, Non-small Cell Lung Cancer1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility8.1e-05 mg/mLALOGPS
logP5.42ALOGPS
logP5.46ChemAxon
logS-6.9ALOGPS
pKa (Strongest Acidic)9.27ChemAxon
pKa (Strongest Basic)8.28ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area97.4 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity166.04 m3·mol-1ChemAxon
Polarizability63.77 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on March 19, 2008 10:23 / Updated on June 04, 2019 06:23